Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland
07 March 2013
(30.75 Kb 8 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013